Tenderwize
Zurück zur Suche

Epinephrine (ATC C01CA24)

AOK - Die Gesundheitskasse in Hessen·Bad Homburg, Germany·Deadline Dec 01, 2026 · 98 days left·Open·Supplies
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V (Open-House-Modell)

38/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

38 / 100

Komplexität

42 / 100

Risikofaktoren

Structured data says electronic submission is not allowed, while the XML notice text says prior electronic submission b...

The XML notice text states that the Epinephrin procedure is withdrawn/terminated on 28.02.2026, which may affect whethe...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Jan 2027
  • Conclusion of non-exclusive rebate agreements under §130a(8) SGB V for finished medicinal products with various active substances or combinations.
  • Open-house model: accession/contract conclusion possible at any time under identical conditions.
Vollständige Zusammenfassung anzeigen

This is an open-house notice for non-exclusive rebate agreements under §130a(8) SGB V for pharmaceutical products (CPV 33600000) in Germany, led by AOK - Die Gesundheitskasse in Hessen. The notice states that accession/contract conclusion is possible at any time on the same conditions, with no individual negotiations. One lot is explicitly identified: Epinephrin (ATC C01CA24), but the lot is also stated to be withdrawn/terminated on 28.02.2026. No contract value is provided. Electronic submission is not allowed; the XML text indicates prior email submission to the buyer contact, which is an inconsistency to note.

Risiken

Structured data says electronic submission is not allowed, while the XML notice text says prior electronic submission b...

The XML notice text states that the Epinephrin procedure is withdrawn/terminated on 28.02.2026, which may affect whethe...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Administrative

  • Submission language is German.
  • Electronic submission is not allowed according to structured data.
  • The XML notice states prior electronic submission by email to [email protected], which conflicts with the structured electronicSubmission flag.

Auftraggeber

Ort

Bad Homburg, DEU

Website

www.aok.de

Kennung

DE114110216

Tätigkeit

Health

Lose (1)

LOT-0003

Epinephrine (ATC C01CA24)

Open-house rebate agreement for the active substance Epinephrin. The lot is explicitly stated in the XML notice text as being withdrawn/terminated on 28.02.2026, despite also showing a start date of 01.02.2025 and an end date of 31.01.2027 in the structured data. Source: structured data and XML notice text.

SuppliesEU fundedElectronic submission

Ort

Germany

Dauer

Jan 2025 - Jan 2027

Kategorie

Pharmaceutical products

Frist

Deadline Dec 01, 2026

Vergabedetails

Veröffentlichungsdatum
22 Jan 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
51271-2026

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3